SEMAGLUTIDE (glucagon-like peptide-1 (GLP-1) receptor agonist)

Semaglutide is a medication used in combination with diet and exercise to reduce the risk of major cardiovascular events such as death, heart attack or stroke in adults already known to have existing heart disease and a form of obesity and to help anyone over the age of 12 years old with a documented history of obesity or adults that are overweight that have weight related medical problems that would like assistance to lose excess body weight and keep it off. Semaglutide exclusively targets the GLP-1 receptor agonist.

Tirzepatide glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists. It was originally developed and approved as a treatment for type 2 diabetes in conjunction with diet and exercise to improve glycemic control.

Unlike the popular well known glucagon-like peptide-1 (GLP-1) receptor agonist medication Semaglutide and unlike Tirzepatide which binds to and activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), Retatrutide has been called a “triple threat”, targeting glucagon (GCG) in addition to GLP-1 and GIP.